Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) ...
https://www.google.com/url?rct=j&sa=t&url=https://www.businesswire.com/news/home/20220720005547/en/Lysogene-Reports-its-Cash-Position-as-of-30-June-2022&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw1t5G-UnxuFPzR8bezfiUG1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.